Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00387
2014-01-14
Prospective
CRE-2013.600-T
Department of Paediatrics
Department of Paediatrics, The Chinese University of Hong Kong
N/A
Chun Ting Au
Department of Pediatrics, 6th Floor, Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
26322982
junau@cuhk.edu.hk
Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong
Albert Martin Li
Department of Pediatrics, 6th Floor, Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong
26322917
albertmli@cuhk.edu.hk
Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong
A randomized study of intranasal corticosteroid for childhood primary snoring – endothelial function perspective
Impact of intranasal corticosteroid on endothelial function of children with primary snoring
類固醇噴鼻治療對原發性鼻鼾症兒童的血管內皮細胞功能之影響
intranasal corticosteroid on endothelial for endothelial function of children with primary snoring
Hong Kong
Yes
2013-12-13
primary snoring
Drug
budesonide 32mcg one spray per nostril once daily
4 months
N/A, watchful waiting as controls
(i) Hong Kong Chinese children and adolescents aged between 8-16 years.
(ii) Normal sleep study as documented on PSG (OAHI <1).
(iii) Non-smoker.
(iv) Written informed consent obtained from parents.
(i) Obesity, defined as having a body mass index (BMI) ≥95th percentile (corresponding to a z score of 1.645) of the local reference.[20]
(ii) Known medical conditions that could affect airway, BP control and endothelial function, for example cranio-facial, neuromuscular diseases and congenital heart disease.
(iii) Receiving medications that could alter BP control and endothelial function.
(iv) Upper respiratory tract or other infection within the past 4 weeks from recruitment.
8
16
Both Male and Female
Interventional
Randomized
Placebo
Single-blind
Parallel
2014-04-01
104
Recruiting
flow-mediated dilatation of brachial artery
N/A
2015-08-17
ChiCTR-TRC-14004138
Yes
N/A
|
|
|
|
|
---|---|---|---|---|
No documents yet. |